alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. The journal of prevention of Alzheimer's disease 2017 Clinical trials

    In APOE4/4 homozygotes receiving 150mg BID tramiprosate, efficacy in the traditional Mild AD patients (MMSE 20-26) was higher than the overall group (MMSE 16-26) and efficacy in the Mild patients (MMSE 22-26) was highest.

  2. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Geriatrics & gerontology international 2015-12-29 Clinical trials

    Four-week changes in NPI-Q total scores did not differ significantly between the treatment and placebo groups.

  3. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Movement disorders : official journal of the Movement Disorder Society 2015-04-25 Cognitive tests and assessment

    Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life.

  4. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Journal of general internal medicine 2015-01-10 Drug development

    Statin therapy was not associated with cognitive impairment in RCTs.

  5. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Mayo Clinic proceedings 2013-10-01 Drug development

    In patients without baseline cognitive dysfunction, short-term data are most compatible with no adverse effect of statins on cognition, and long-term data may support a beneficial role for statins in the prevention of dementia.

  6. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2012-06-05 Treatments

    Antibody administration was well tolerated with doses up to 400 mg weekly.

  7. Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Annals of Internal Medicine 2007-10-16 Costs and economics

    Letters16 October 2007Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial FibrillationRobert G. The study's important results indicate that the relative efficacy and safety of warfarin for stroke prevention can be extended to very elderly patients who are managed by nonspecialists.

  8. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. JAMA 2003-01-01 Treatments

    Cholinergic dysfunction is also associated with neuropsychiatric and functional deficits, but results from randomized controlled trials of cholinesterase inhibitors are conflicting.

  9. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Annals of neurology 2002-09-01 Drug development

    In a randomized, placebo-controlled, double-blind study, we investigated whether statins alter cholesterol metabolites and reduce Abeta levels in the cerebrospinal fluid of 44 patients with Alzheimer's disease.

  10. Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-06 Biomarkers

    Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels.

  11. Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA network open 2024-10-01 Treatments

    There were 132 846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159 419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92 328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]).

  12. Effects of lithium on serum Brain-Derived Neurotrophic Factor in Alzheimer's patients with agitation

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. International journal of geriatric psychiatry 2023-09 Drug development

    BDNF levels did not change significantly and were not associated with improvement in overall neuropsychiatric symptoms or in cognitive function.

  13. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. The journal of prevention of Alzheimer's disease 2023 Clinical trials

    A total of 1795 participants were enrolled (lecanemab:898; placebo:897).

  14. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. The British journal of psychiatry : the journal of mental science 2019-11 Drug development

    Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years.

  15. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Journal of Alzheimer's disease : JAD 2019 Clinical trials

    The safety profile was similar for 20 μg treatment and placebo patients.

  16. A phase II trial of tideglusib in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Journal of Alzheimer's disease : JAD 2015-01-01 Tau biomarkers

    Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial.

  17. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Journal of Alzheimer's disease : JAD 2010-01-01 Clinical trials

    PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD).

  18. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. The Lancet. Neurology 2009-06-10 Treatments

    72 patients with PDD or DLB were randomly assigned and started treatment: 34 with memantine and 38 with placebo. 56 (78%) completed the study.

  19. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. The Lancet. Neurology 2008-07-30 Treatments

    Inclusion criteria were early AD (mini-mental state examination [MMSE] score between 20 and 26 points or Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) score between 10 and 25 points), taking a stable dose of acetylcholinesterase inhibitor (donepezil, galantamine, or rivastigmine) for at least 4 months, a modified Hachinski score of 4 points or less, and CT or MRI results that were consistent with AD.

  20. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. International journal of geriatric psychiatry 2002-12 Clinical trials

    Twenty-five out of 44 completed the trial.

  21. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1997-05 Clinical trials

    No difference was seen in Clinical Global Impression scores between patients receiving placebo and those receiving linopirdine (n = 189).

  22. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's & dementia (New York, N. Y.) 2022-02-23 Drug development

    Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

  23. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. BMJ (Clinical research ed.) 2021-02-25 Treatments

    Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition.

  24. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2016-03-01 Treatments

    Based on integrated review of laboratory, electrocardiogram, adverse events, and MRI, AAB-003 was safe and well tolerated up to 8 mg/kg for up to 91 weeks (FIH and extension trials) in patients with mild to moderate AD.

  25. Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Journal of Alzheimer's disease : JAD 2016-01-01 Drug development

    Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD).

From across this topic

10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics